At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ORIC Oric Pharmaceuticals Inc.
Closed 01-02 16:00:00 EST
8.17
-0.01
-0.12%
盘后8.17
+0.000.00%
19:11 EST
High8.33Low8.04Vol805.55K
Open8.24D1 Closing8.18Amplitude3.55%
Mkt Cap795.67MTradable Cap495.58MTotal Shares97.39M
T/O6.58MT/O Rate1.33%Tradable Shares60.66M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BUZZ-India's Orient Technologies rises after shareholders approve bonus issue
Reuters  ·  2025-12-30
BUZZ-India's Orient Technologies rises after shareholders approve bonus issue
Oric Pharmaceuticals Currently Down Eight Consecutive Days, On Track for Longest Losing Streak Since June 2024 -- Data Talk
Dow Jones  ·  2025-12-17
Oric Pharmaceuticals Currently Down Eight Consecutive Days, On Track for Longest Losing Streak Since June 2024 -- Data Talk
ORIC Pharmaceuticals (ORIC): Valuation Check After Encouraging Enozertinib Phase 1b Lung Cancer Data
Simply Wall St.  ·  2025-12-09
ORIC Pharmaceuticals (ORIC): Valuation Check After Encouraging Enozertinib Phase 1b Lung Cancer Data
Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush
Dow Jones  ·  2025-12-08
Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush
Oric Pharmaceuticals Grants Stock Options and Restricted Stock Units to New Employees
Reuters  ·  2025-12-06
Oric Pharmaceuticals Grants Stock Options and Restricted Stock Units to New Employees
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  2025-12-06
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  2025-12-06
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Oric Pharmaceuticals Reports Promising Phase 1b Results for Enozertinib in NSCLC Patients with EGFR Mutations
Reuters  ·  2025-12-05
Oric Pharmaceuticals Reports Promising Phase 1b Results for Enozertinib in NSCLC Patients with EGFR Mutations
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
GlobeNewswire  ·  2025-12-05
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
Oric Pharmaceuticals Showcases Enozertinib Data at ESMO Asia Congress 2025
Reuters  ·  2025-12-04
Oric Pharmaceuticals Showcases Enozertinib Data at ESMO Asia Congress 2025
Oric® Pharmaceuticals Announces Enozertinib (Oric-114) Late-Breaking Oral Presentations in Egfr Atypical and Egfr Exon 20 Nsclc at the Esmo Asia Congress 2025
THOMSON REUTERS  ·  2025-12-04
Oric® Pharmaceuticals Announces Enozertinib (Oric-114) Late-Breaking Oral Presentations in Egfr Atypical and Egfr Exon 20 Nsclc at the Esmo Asia Congress 2025
ORIC Pharmaceuticals (ORIC): Assessing Valuation as New Enozertinib Clinical Data Sparks Investor Interest
Simply Wall St.  ·  2025-12-02
ORIC Pharmaceuticals (ORIC): Assessing Valuation as New Enozertinib Clinical Data Sparks Investor Interest
Oric Pharmaceuticals Unveils Phase 1b Data for Enozertinib in HER2 Exon 20 NSCLC at ESMO Asia 2025
Reuters  ·  2025-12-01
Oric Pharmaceuticals Unveils Phase 1b Data for Enozertinib in HER2 Exon 20 NSCLC at ESMO Asia 2025
ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
GlobeNewswire  ·  2025-11-25
ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
Stock Track | Oric Pharmaceuticals Surges 5.92% Pre-market on Positive Analyst Coverage
Stock Track  ·  2025-11-20
Stock Track | Oric Pharmaceuticals Surges 5.92% Pre-market on Positive Analyst Coverage
Oric Pharmaceuticals Initiated at Outperform by Evercore ISI Group
Dow Jones  ·  2025-11-20
Oric Pharmaceuticals Initiated at Outperform by Evercore ISI Group
Oric Pharmaceuticals initiated with an Outperform at Evercore ISI
TIPRANKS  ·  2025-11-20
Oric Pharmaceuticals initiated with an Outperform at Evercore ISI
ORIC Pharmaceuticals Q3 Net Income USD -32.587 Million
Reuters  ·  2025-11-20
ORIC Pharmaceuticals Q3 Net Income USD -32.587 Million
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  2025-11-20
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Oric Pharmaceuticals Initiated at Peer Perform by Wolfe Research
Dow Jones  ·  2025-11-19
Oric Pharmaceuticals Initiated at Peer Perform by Wolfe Research

Introduction

Company Name.
Oric Pharmaceuticals Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Issue price:
--